Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer
Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer
复制标题
DOI：
10.26355/eurrev_201804_14752
复制
发表时间：
2018-04-01
影响因子：
3.3
通讯作者：
Favuzzi, A. M. R.
中科院分区：
文献类型：
--
作者：
Nicolazzi, M. A.;Carnicelli, A.;Favuzzi, A. M. R.
目的：乳腺癌是女性最常见的恶性肿瘤。在过去的二十年中，针对特定分子靶点的早期诊断、新辅助治疗和辅助全身治疗显著降低了乳腺癌的死亡率。然而，生存率的增加使人们能够观察到抗癌治疗的心脏毒性作用和心血管原因导致的死亡率增加，从而产生了大量文献，专家们试图确定这一关键问题的正确管理。即使在这一领域的关注增加，许多问题还没有答案，新的研究是needed.MATERIALS和METHODS：我们进行了广泛的搜索，在Medline的英文文献，使用以下检索词：心脏毒性，蒽环类药物，曲妥珠单抗，乳腺癌，左心室功能障碍，心力衰竭。手动检查的文章发现已经performed.RESULTS：我们提供了一个全面的评估，目前的知识蒽环类药物加曲妥珠单抗诱导的心脏毒性的妇女受乳腺癌。CONCLUSIONS：早期识别和及时治疗的亚临床心脏毒性可能会改善这些患者的心脏预后，并可能允许肿瘤学家，以避免化疗的退出。这就是为什么建立多学科团队变得更加重要，心脏病学家和肿瘤学家共同努力，以确保对接受心脏毒性药物治疗的肿瘤患者进行最佳护理。
OBJECTIVE: Breast cancer is the most common cancer among women. In the last twenty years early diagnosis, neoadjuvant and adjuvant systemic treatment that targeted to specific molecular targets have significantly reduced the mortality from breast cancer. However, the increase in survival has allowed to observe the cardiotoxic effects of anticancer therapy and increased mortality from cardiovascular causes, resulting in a large literature where experts try to identify the correct management of this critical problem. Even thought the increased attention in this field, many questions have not yet answers and new studies are needed.MATERIALS AND METHODS: We conducted a broad search of the English-language literature in Medline using the following search terms: cardiotoxicity, anthracyclines, trastuzumab, breast cancer, left ventricular dysfunction, heart failure. A manual examination of the articles found has been performed.RESULTS: We provide a comprehensive assessment of the current knowledge about cardiotoxicity induced by anthracycline plus trastuzumab in women affected by breast cancer.CONCLUSIONS: Early identification and prompt treatment of subclinical cardiotoxicity may improve cardiologic prognosis of these patients and may allow oncologists to avoid withdrawal of chemotherapy. That is why it becomes always more important the creation of multidisciplinary teams where cardiologists and oncologists work together to ensure optimal care to oncologic patients treated with cardiotoxic agents.